EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up

Martin Desrosiers, Zuzana Diamant, Paolo Castelnuovo, Peter W Hellings, Joseph K Han, Anju T Peters, Jared Silver, Steven G Smith, Abigail Fuller, Ana R Sousa, Robert H Chan, Philippe Gevaert und 1 weitere

International Forum of Allergy & Rhinology · 2024

DOI: 10.1002/alr.23219 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Martin Desrosiers und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Nasal Polyps, Rhinitis, Rhinosinusitis. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK, GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the 52‐week Phase III SYNAPSE study, mepolizumab given every 4 weeks (100 mg subcutaneously) reduced nasal polyp (NP) size, improved symptoms and quality of life (QoL), and reduced corticosteroid use and number of sinus surgeries in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), versus placebo. Because the durability of mepolizumab's efficacy after discontinuation is poorly understood in CRSwNP, the efficacy of mepolizumab after discontinuation was analyzed in severe CRSwNP, over a 24‐week follow‐up.

Methods

Changes from SYNAPSE baseline to end of treatment (week 52) and end of follow‐up (week 76) were assessed for total endoscopic NP score, nasal obstruction and overall symptoms visual analog scale scores, and 22‐item Sino‐Nasal Outcome Test score. Time to first sinus surgery, time to first corticosteroid use, and geometric mean blood eosinophil counts (BECs) were also assessed.

Results

Among 134 follow‐up patients, clinical improvements observed with mepolizumab versus placebo were partially evident 24 weeks after discontinuation despite BEC returning to baseline. The mean (95% confidence interval [CI]) change from baseline in NP score (week 52: −1.3 [1.8 to −0.9] vs. −0.3 [−0.6 to 0.1]; week 76: −1.2 [−1.6 to −0.7] vs. −0.1 [−0.5 to 0.3]) and the proportion of patients having sinus surgery (week 52: 4% vs. 25%; week 76: 9% vs. 31%) remained substantially improved with mepolizumab versus placebo. Mepolizumab‐associated improvements in overall symptoms, quality of life, and corticosteroid use versus placebo were partially sustained at week 76.

Conclusion

Fifty‐two weeks of mepolizumab treatment is associated with sustained clinical benefits up to 24 weeks after discontinuation in patients with severe CRSwNP, which should be considered by physicians when making treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNasal PolypsRhinitisRhinosinusitisSinusitisHumansAdrenal Cortex HormonesChronic DiseaseFollow-Up StudiesQuality of LifeDouble-Blind Method

Stichwörter der Autor:innen

biologic therapychronic rhinosinusitis with nasal polypsdurabilityefficacymepolizumabsinus surgery

Substanzen

Adrenal Cortex HormonesAntibodies, Monoclonal, Humanizedmepolizumab

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Québec, Canada.
  • Department of Allergy and Clinical Immunology, KU Leuven, Catholic University of Leuven, Leuven, Belgium.
  • Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
  • Respiratory Medicine and Allergology, Skane University, Lund, Sweden.
  • Department of Biotechnology and Life Science, University of Insubria, Varese, Italy.
  • Upload Research Centre, University of Insubiria, Varese, Italy.

Förderung

  • GSK
  • GlaxoSmithKline

Zitieren

APA

Desrosiers, M., Diamant, Z., Castelnuovo, P., Hellings, P. W., Han, J. K., Peters, A. T., Silver, J., Smith, S. G., Fuller, A., Sousa, A. R., Chan, R. H., Gevaert, P., & SYNAPSE study investigators (2024). Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23219

Vancouver

Desrosiers M, Diamant Z, Castelnuovo P, Hellings PW, Han JK, Peters AT, et al. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23219

BibTeX
@article{Desrosiers2024,
  author = {Desrosiers, Martin and Diamant, Zuzana and Castelnuovo, Paolo and Hellings, Peter W and Han, Joseph K and Peters, Anju T and Silver, Jared and Smith, Steven G and Fuller, Abigail and Sousa, Ana R and Chan, Robert H and Gevaert, Philippe and SYNAPSE study investigators, SYNAPSE study investigators},
  title = {Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up},
  journal = {International Forum of Allergy & Rhinology},
  year = {2024},
  doi = {10.1002/alr.23219}
}
Kostenlos starten →